Is 9960.HK overvalued or undervalued?

9960.HK currently has a P/E ratio of -19.60. Relative to the sector average of 26.80, this suggests the stock may be undervalued. A higher P/E than peers means investors are paying more for each unit of earnings, often because they expect faster future growth. However, if that growth does not materialize, the stock can appear overvalued. A lower P/E may indicate weaker growth expectations or higher risk, but it can also signal a potential valuation discount.

How can I buy Kindstar Globalgene Technology, Inc. stock?

Kindstar Globalgene Technology, Inc. trades on HKSE. Investors in Latin America can buy it through international and regional brokerage and investment platforms. You simply need a valid government ID or passport to get started.

Can I buy fractional shares of 9960.HK?

Yes. Through fractional investing, you can invest exactly the amount you want, starting with as little as $1 or $5 USD (depending on what investment platform you use), and own a proportional piece of the company.

Does buying 9960.HK protect my money against local inflation?

Many investors in Latin America buy international stocks like 9960.HK to protect their purchasing power. Because 9960.HK is priced in foreign currency, your investment is tied to a hard currency. If your local currency devalues against the foreign currency, usually USD or Euro, the underlying value of your stock portfolio remains protected from local inflation.

Do I need a foreign bank account or a Visa to buy 9960.HK shares?

No. A common misconception is that you need a foreign bank account or a foreign visa to invest in international stocks. Today, modern investment platforms allow you to fund your account using local bank transfers or local payment methods right from your home country.

Is 9960.HK a suitable investment for my portfolio?

There is no universal answer, since fit depends on your situation, not just the stock. Think about three things: how well 9960.HK diversifies what you already own, whether you can stomach its price swings given your risk tolerance, and how long you plan to stay invested. As a rule, a single stock works best as one piece of a broader asset allocation and with a multi-year time horizon. This is general information, not personalized financial advice.

All stocks9960.HK

Kindstar Globalgene Technology, Inc.

HK$0.94+HK$0.03+3.30%

HKSE / HKD

Market cap

HK$971M

P/E

-19.6

EPS (TTM)

HK$-0.01

Dividend yield

10.11%

Beta

0.63

1Y return

-36.91%

Deposit US$200 and get US$50 for freeT&C apply. Your capital is at risk.Invest with

Compare, tap a companyup to 2 at once

Deposit US$200 and get US$50 for freeT&C apply. Your capital is at risk.Invest with

Financials

The numbers behind the company

Revenue vs net income

RevenueNet income

$146M2021

$201M2022

$136M2023

$127M2024

$133M2025

Financial health

Gross margin

Operating margin

ROE

ROA

Debt to equity0.15Low
Current ratio2.84
Cash ratio0.77
Net margin-4.4%
Free cash flow—

Valuation

Is it expensive right now

P/E vs the market

scale 0–50

0153050

9960.HK-19.6
Healthcare sector median26.8
S&P 50022.0

Trades about 173% below its sector, cheaper than its peers on earnings.

Ratios

PEG-0.21
Price to book0.31
EPS (TTM)HK$-0.01
Payout ratio-5,310%
FCF yield4.37%

Range & risk

HK$0.90HK$1.51

Trading in the lower third of its 52-week band

Beta0.63

Profile

What Kindstar Globalgene Technology, Inc. actually does

Kindstar Global (Beijing) Technology, Inc. is a prominent provider of highly specialized diagnostic services to healthcare institutions across China. Beyond just diagnostics, the company extends its expertise to support medical research, clinical drug trials, and translational medicine initiatives for a diverse client base, including individual practitioners, research organizations, various hospital types, and pharmaceutical firms. This broad service portfolio is underpinned by its extensive, state-of-the-art laboratory infrastructure, which encompasses disciplines such as flow cytometry, cytogenetics, medical genomics, molecular biology, hematopathology, mass spectrometry, pathology, clinical immunology, and microbiology, alongside dedicated scientific research labs. Kindstar Global offers a comprehensive range of diagnostic tests covering key areas like hematology (blood), oncology (tumor), and genetic disorders. Its capabilities also extend to diseases affecting the cardiovascular and cerebrovascular systems, infectious agents, and autoimmune conditions, supporting various medical specialties including internal medicine, surgery, gynecology, pediatrics, and numerous other clinical fields. Established in 2003, the company maintains its headquarters in Wuhan, China.

CEO

Shiang Huang

Employees

2,999

Headquarters

Wuhan, HB

Founded

2021-07-16

Company website

If you had invested a decade ago

Loading the full price history…

Run your own numbers

Past performance is not a forecast.

ETFs

Own it inside an ETF instead

Vanguard S&P 500

Vanguard Total Stock Market

Vanguard Total World Stock

Invesco QQQ

SPDR S&P 500

iShares Russell 2000

Community sentiment

Bullish—

Distribution

Bearish0%
Neutral0%
Bullish0%

Track it without buyingTrack it

no account needed

Save 9960.HK and get told when something moves.

Get updates

A clear, direct weekly summary.

Keep looking

Q&A

Questions people ask

9960.HK has a beta of 0.63, which indicates how sensitive it has historically been to movements in its broader market. A beta below 1 indicates lower relative volatility than the market. Beta is based on historical data and does not predict future performance.

Kindstar Globalgene Technology, Inc.